MFDS (South Korea)

MFDS (식품의약품안전처, Ministry of Food and Drug Safety) is South Korea's central regulatory authority for foods, pharmaceuticals, biologics, medical devices, cosmetics + quasi-drugs. MFDS was elevated from the Korea Food and Drug Administration (KFDA) to ministerial level in March 2013 + reports directly to the Prime Minister's Office — a structural elevation that reflects Korean policy prioritisation of regulatory science + life-sciences industry development. MFDS's headquarters is in Cheongju (Osong Bio Valley), with six Regional Offices (Seoul, Busan, Gyeongin, Daegu, Gwangju + Daejeon) handling regional inspections + licensing.

The MFDS ecosystem includes:

• MFDS HQ — central regulatory policy, licensing + enforcement.
• NIFDS — National Institute of Food and Drug Safety Evaluation; the scientific evaluation arm + the equivalent of an FDA CDER / CBER / CDRH evaluation function rolled into one.
• Six Regional Offices — regional inspections, licensing, market surveillance.
• KIDS — Korea Institute of Drug Safety + Risk Management; operates the Korea Adverse Event Reporting System (KAERS) + pharmacovigilance.
• NIDS — National Institute of Medical Device Safety Information; device-specific safety + UDI + surveillance.
• KPIC — Korea Pharmaceutical Information Center; drug information + classification + product database.
• NIBR — National Institute of Biotechnology Research (biotech research; not MFDS but a frequent collaborator).
• NeDrug + eIRB + e-submission portals — Korea's e-submission infrastructure; one of the most digitally advanced regulatory submission systems in Asia.

Legal foundations are the Pharmaceutical Affairs Act (PAA) for medicines, the Medical Devices Act (MDA) for devices, the Cosmetics Act, the Act on Safety of Functional Health Foods, the Advanced Regenerative Bio Act (2019, effective Aug 2020 — the world's second-most progressive ATMP framework after Japan), the Act on Pharmaceutical Affairs of Biological Products, KGMP / KGCP / KGLP / KGCP (Korean Good Manufacturing / Clinical / Laboratory / Clinical Practices) + a body of MFDS Notifications + Administrative Rules that operationalise the Acts.

MFDS achieved ICH Regulatory Membership in November 2016 (the second Asian regulator after PMDA), PIC/S Membership since July 2014, IMDRF Management Committee membership since 2017, MDSAP Affiliate Member status + WHO-Listed Authority status. MFDS is widely recognised as one of the most internationally integrated + scientifically capable regulators in Asia.

Korea's Advanced Regenerative Bio Act (첨단재생의료법) — passed Aug 2019, effective Aug 2020 — is the world's second-most progressive regenerative-medicine framework after Japan's 2014 PMD Act. The Act creates a parallel regulatory framework distinct from the standard PAA, recognising the unique scientific + risk profile of cell + gene therapies + tissue-engineered products.

• Scope — autologous + allogeneic cell therapy, gene therapy, tissue-engineered medical products (TEMPs), combination ATMPs.
• Risk classification — High / Medium / Low risk based on cell origin, manipulation level + intended use.
• Hospital-Based Regenerative Medicine — qualified hospitals can perform low-risk regenerative-medicine procedures under MFDS + MoHW oversight (similar to Japan's 2014 framework).
• Conditional Approval (Advanced Regenerative Biomedical Product, 첨단재생바이오의약품 조건부 허가) — accelerated pathway for serious-disease ATMPs with post-marketing commitments; world-first pathway alongside Japan.
• Korea Cell + Gene Therapy industry — MFDS has approved multiple cell + gene therapies including Invossa (cell therapy for osteoarthritis — withdrawn 2019 after mislabelling), Kymriah (Novartis CAR-T, MFDS-approved 2021), Carvykti (J&J CAR-T) + Korean-developed CAR-Ts.
• Coordination with KCDC / MoHW — Ministry of Health + Welfare (MoHW) coordinates clinical implementation; MFDS regulates product approval; tight collaboration on hospital-based + product-based pathways.
• GIFT designation — many ATMPs receive GIFT priority-review designation for accelerated MFDS review.

• Class I — Lowest risk; notification (신고) to MFDS Regional Office.
• Class II — Low-moderate risk; certification (인증) via MFDS-designated Recognised Certification Body.
• Class III — Moderate-high risk; approval (허가) by MFDS HQ / NIFDS.
• Class IV — Highest risk; approval (허가) by MFDS HQ / NIFDS with most stringent evidence requirements.
• KGMP for devices — substantively aligned with ISO 13485:2016; KGMP certification required for manufacturing licence.
• MDSAP recognition — MFDS is MDSAP Affiliate Member; MDSAP audit reports accepted as part of KGMP evidence package (formal recognition progressively expanding).
• Notified Body / Recognised Certification Body model — MFDS designates Korean RCBs to perform Class II certification + KGMP audits; substantively similar to EU Notified Body model.
• Clinical evidence — Class III + IV typically require Korean clinical-investigation data or accepted foreign clinical evidence; Class II may use literature + comparator data.
• Korea UDI — implemented progressively from 2019; mandatory UDI on Class IV (2019), Class III (2020), Class II (2021), Class I (2022); GS1 issuing agency primary.
• Innovative Medical Device pathway (혁신의료기기) — accelerated review for innovative devices including SaMD, AI-based devices, novel implants.
• Re-evaluation — periodic re-evaluation of approved devices; MFDS may re-examine safety + efficacy at intervals.
• Import licence — foreign-manufactured devices require Korean Marketing Authorisation Holder (KMAH) + KGMP-equivalence + import licence.

• KGMP for drugs — Korean Good Manufacturing Practice; substantively aligned with PIC/S GMP Guide + ICH Q7 / Q9 / Q10; MFDS Notification details + Annexes parallel PIC/S Annexes.
• KGMP for devices — substantively aligned with ISO 13485:2016 + MDSAP requirements.
• KGMP for ATMPs — specific Annex covering cell + gene therapy + tissue-engineered products; aligned with PIC/S Annex 2A / 2B + EU GMP Annex 2A.
• PIC/S Member since Jul 2014 — full reliance under PIC/S MoU; MFDS inspection reports accepted by all PIC/S members + vice-versa.
• MRA + bilateral arrangements — MFDS has GMP MRAs / arrangements with EU (under PIC/S), Switzerland, Japan + cooperation arrangements with FDA + Health Canada.
• Overseas inspections — MFDS conducts overseas inspections of foreign sites supplying Korea; risk-based programme prioritising new drug applications + biologics.
• Data integrity — MFDS Data Integrity Guideline (2018, updated 2022) substantively aligned with MHRA + PIC/S PI 041; ALCOA+ + audit-trail + computerised-systems expectations.
• Inspection findings + remediation — MFDS issues Inspection Reports + Warning Letters + manufacturing-licence suspension; published market actions on MFDS portal.
• Korea Pharmaceutical Manufacturers Association (KPMA) — industry body coordinating with MFDS on KGMP implementation + training.

• KAERS (Korea Adverse Event Reporting System) — operated by KIDS; the central Korean pharmacovigilance database; E2B(R3)-compliant; integrated with WHO VigiBase via UMC Uppsala.
• ICSR reporting — Serious unexpected ADRs within 15 calendar days; serious expected within 30 days; non-serious in periodic reports.
• PSUR — periodic safety update reports per ICH E2C(R2); harmonised with EU + ICH PSUR cycle; KIDS reviews + summarises.
• Risk Management Plan (RMP) — required for new drugs + biosimilars; per ICH E2E + MFDS RMP guidance.
• Re-examination System (재심사 제도) — modelled on Japanese PMDA; 4-6 year post-marketing surveillance for new drugs (typically 4 for generics-of-new-drugs, 6 for new chemical entities); MAH conducts post-marketing surveillance + submits Periodic Safety Reports.
• Re-evaluation System (재평가 제도) — periodic re-evaluation of all approved drugs at MFDS-specified intervals.
• Korea Drug + Device Vigilance Action Plan — coordinated MFDS + KIDS + NIDS programme.
• Materiovigilance (의료기기 부작용) — operated by NIDS; device-specific adverse-event reporting + UDI-linked surveillance.
• Drug Shortages — MFDS Drug Shortage System; MAHs must report supply disruptions.
• Recall — Class I / II / III recall framework; coordinated MFDS + KIDS execution.

• ICH Regulatory Member since Nov 2016 — second Asian regulator after PMDA; MFDS actively contributes to ICH Working Groups + adopts ICH guidelines via MFDS Notifications.
• PIC/S Member since Jul 2014 — MFDS PIC/S full participation enabling worldwide GMP reliance.
• IMDRF Management Committee Member since 2017 — active on UDI, SaMD, AI / ML, QMS work products.
• MDSAP Affiliate Member — MDSAP audit reports accepted as KGMP evidence; formal Member status progressing.
• ICMRA — MFDS active on pandemic preparedness, supply chain, regulatory innovation, generics.
• WHO Listed Authority — MFDS-approved Korean vaccines + biologics + biosimilars are major WHO PQ contributors.
• ACCSQ-PPWG — ASEAN pharmaceutical product working group; MFDS observer + cooperation partner.
• Korea-Japan-China Tripartite — annual heads-of-regulator meetings + technical cooperation; particularly close PMDA-MFDS-NMPA dialogue.
• Bilateral MRAs + cooperation arrangements — EU (PIC/S), Switzerland, Japan, Singapore + MoUs with FDA + Health Canada + MHRA + TGA + many others.
• APEC Regulatory Harmonization Steering Committee (RHSC) — MFDS active member.

• Korean MAH (KMAH) not properly designated for imported products — application rejected at intake.
• KGMP certificate expired or not issued for the specific dosage form / manufacturing site.
• Korean-language labelling + IFU non-compliant — Korean labelling must be a faithful translation + include all MFDS-required elements.
• BE study not conducted at MFDS-recognised BE centre — generic application rejected.
• Re-examination Periodic Safety Report missed or late — MFDS may suspend or cancel licence.
• KAERS ICSR reporting timelines missed — pharmacovigilance enforcement action.
• Risk Management Plan not updated for new safety signals — MFDS Inspection finding.
• Data integrity findings — backdating, audit-trail disabled, shared logins, uncontrolled spreadsheets used as raw data.
• KGMP Annex deviations — clean-room qualification, environmental monitoring, aseptic-process simulation gaps.
• Foreign-GMP evidence package incomplete — relying solely on home-country GMP without PIC/S MRA verification or MFDS on-site inspection arrangement.
• Class III / IV device clinical-evidence gap — Korean clinical data or accepted foreign clinical evidence required, not just literature.
• Korea UDI implementation gap — missing UDI on labels, UDI-DI mismatch with MFDS database, packaging-hierarchy errors.
• ATMP donor + traceability records inadequate — Advanced Regenerative Bio Act + KGMP ATMP Annex requirements.
• Hospital-Based Regenerative Medicine + MoHW coordination gap — applicants confusing MFDS product approval with MoHW hospital-procedure oversight.
• PSUR not aligned with International Birth Date — Korean PSUR cycle out of sync with ICH PSUR submissions to other regulators.

V5 Ultimate provides the operational infrastructure Korean + foreign-supplier sites need for KGMP + Medical Devices Act + Advanced Regenerative Bio Act compliance + MFDS readiness.

• KGMP control framework — Schedule M-equivalent + Annex-aligned controls (clean rooms, aseptic process, environmental monitoring, computerised systems) with ALCOA+ data-integrity + Korean MFDS Data Integrity Guideline alignment.
• Korean MAH (KMAH) workflow — KMAH-of-record designation, KGMP certificate tracking, foreign manufacturer KGMP-equivalence packaging for imported products.
• NeDrug + eIRB submission packaging — eCTD-aligned dossier structure with Korean Module 1 specifics, Korean-language labelling + IFU artwork control, MFDS submission tracking.
• Medical Devices Act licensing workflow — Class I notification, Class II certification via Recognised Certification Body, Class III / IV approval via MFDS HQ; KGMP for devices + ISO 13485 + MDSAP audit-report alignment.
• Korea UDI — UDI-DI assignment per GS1 issuing agency, packaging-hierarchy management, MFDS UDI database submission, Class-by-Class timeline tracking from 2019-2022 rollout.
• Advanced Regenerative Bio Act workflow — High / Medium / Low risk classification, GIFT designation tracking, Hospital-Based vs Product-Based pathway management, ATMP donor + traceability + KGMP ATMP Annex compliance.
• Re-examination + Re-evaluation lifecycle — 4-6 year post-marketing surveillance scheduling, Periodic Safety Report packaging, KIDS submission workflow.
• KAERS pharmacovigilance — E2B(R3) ICSR generation, 15-day SUSAR + 30-day serious-expected timelines, PSUR / RMP packaging, KIDS submission tracking.
• Materiovigilance — device adverse-event reporting via NIDS, UDI-linked surveillance, field-safety-corrective-action (FSCA) coordination.
• Korean-language artwork + labelling — Korean translation workflow with two-person review + e-signature; MFDS-required elements + warnings + storage conditions + KMAH details.
• MFDS inspection readiness — MFDS Inspection Plan packaging, KGMP self-inspection checklists, deficiency-tracking + CAPA + remediation timelines.
• Korea-Japan-China Tripartite alignment — for companies operating across all three jurisdictions, V5 surfaces cross-jurisdiction differences in re-examination, post-marketing surveillance + risk management.